DataMeds AI Stock (MEDS)

Upside – $IRON +52% (Phase 3 APOLLO trial met all primary and secondary endpoints in erythropoietic protoporphyria) – $AAME +41% (long-delayed 2025 annual report was filed, showing a return to annual profitability) – $XLAB +24% (extends rally after securing an $8.2M AI-server order) – $TCRT +20% (extends volatile rally tied to a proposed acquisition and …

Upside – $GIXI +135.0% (autonomous robots begin delivering blood and bone marrow at a major hospital, expanding an existing chemotherapy-logistics deployment) – $CCC +10.5% (GTCR and Elliott are reportedly in advanced acquisition talks, with a deal potentially coming this week) – $MEDS +7.0% (Humana adds the ChemoFx gynecologic-cancer assay to a Medicaid coverage policy) – …

Upside – $MEDS +36% (preliminary September pharmacy revenue exceeded $1M, rising more than 66% from July) – $ACN +17% (Q4 beat with $22.2B of bookings and stronger operating margins) – $ABAT +13% (receives federal approval to export up to $100M of recycled black-mass material) – $QSI +13% (no clear fresh catalyst identified; unusually large move …

Upside – $KOD +60% (pivotal Phase 3 DAYBREAK wet-AMD trial met its primary noninferiority endpoints, with most patients reaching a 24-week dosing interval) – $ARAY +39% (agrees to explore integrating Samsung NeuroLogica volumetric imaging technology with the CyberKnife platform) – $MEDS +28% (launches a GLP-1 care app offering telehealth consultations and access to branded medications) …

Upside – $MEDS +30% (litigation settlement is expected to extinguish about $19 million of liabilities and retire 364,099 shares) – $USDE +17%, $PURR +7.0%, $MSTR +2.8%, $HOOD +2.2% (crypto and tokenization-linked stocks rise as Bitcoin rallies and regulators grant temporary relief for tokenized U.S. stock trading) – $STUB +6.0% (Citi upgrades to Buy from Neutral) …